Found: 41
Select item for more details and to access through your institution.
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 2, p. 97, doi. 10.1016/j.clgc.2021.08.001
- By:
- Publication type:
- Article
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
- Published in:
- Journal of Neurosurgery: Spine, 2023, v. 39, n. 2, p. 278, doi. 10.3171/2023.3.SPINE221086
- By:
- Publication type:
- Article
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2015, v. 17, p. 936, doi. 10.4103/1008-682X.150843
- By:
- Publication type:
- Article
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2015, v. 17, n. 6, p. 936, doi. 10.4103/1008-682X.150843
- By:
- Publication type:
- Article
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1432286
- By:
- Publication type:
- Article
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262411
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate- Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262411
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with 18F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262411
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on ProstateSpecific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262411
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPvL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate- Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 33, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging.
- Published in:
- Annals of Nuclear Medicine, 2023, v. 37, n. 4, p. 246, doi. 10.1007/s12149-023-01823-2
- By:
- Publication type:
- Article
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup>F-DCFPyL PET/CT.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
- Published in:
- Prostate, 2020, v. 80, n. 5, p. 407, doi. 10.1002/pros.23955
- By:
- Publication type:
- Article
Characterization of novel cell lines derived from a MYC‐driven murine model of lethal metastatic adenocarcinoma of the prostate.
- Published in:
- Prostate, 2018, v. 78, n. 13, p. 992, doi. 10.1002/pros.23657
- By:
- Publication type:
- Article
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer.
- Published in:
- Prostate, 2018, v. 78, n. 5, p. 401, doi. 10.1002/pros.23484
- By:
- Publication type:
- Article
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
- Published in:
- Prostate, 2016, v. 76, n. 16, p. 1484, doi. 10.1002/pros.23232
- By:
- Publication type:
- Article
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
- Published in:
- Prostate, 2024, v. 84, n. 10, p. 954, doi. 10.1002/pros.24712
- By:
- Publication type:
- Article
Test–retest repeatability of organ uptake on PSMA‐targeted <sup>18</sup>F‐DCFPyL PET/CT in patients with prostate cancer.
- Published in:
- Prostate, 2023, v. 83, n. 12, p. 1186, doi. 10.1002/pros.24577
- By:
- Publication type:
- Article
Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup>F‐DCFPyL test–retest cohort.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 547, doi. 10.1002/pros.24483
- By:
- Publication type:
- Article
Bipolar androgen therapy (BAT): A patient's guide.
- Published in:
- Prostate, 2022, v. 82, n. 7, p. 753, doi. 10.1002/pros.24328
- By:
- Publication type:
- Article
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. 794, doi. 10.1093/oncolo/oyae120
- By:
- Publication type:
- Article
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. 465, doi. 10.1093/oncolo/oyad055
- By:
- Publication type:
- Article
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18 F-DCFPyL.
- Published in:
- Molecular Imaging, 2023, p. 1, doi. 10.1155/2022/7056983
- By:
- Publication type:
- Article
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18 F-DCFPyL.
- Published in:
- Molecular Imaging, 2022, p. 1, doi. 10.1155/2022/7056983
- By:
- Publication type:
- Article
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [<sup>18</sup>F]DCFPyL PET/CT.
- Published in:
- 2019
- By:
- Publication type:
- journal article